My Cart
You have no items in your shopping cart.
Background
The human GRIN1/GRIN2A genes encode the cationic-selective, n-methyl-d-aspartic acid receptor-channel expressed in the CNS. NMDA receptors are therapeutic targets in treatment of neurological disorders including seizure, pain, and Alzheimer's disease.
| General Info | |
| Synonyms | GluN1/GluN2A |
|---|---|
| Product Description | Human NMDA (NR1/NR2A) Receptor-expressing, transiently transfected cells. |
| Target Type | Ion Channel |
| Product Type | EZCells™ TT |
| Family | Ligand-Gated |
| Receptor | Glutamate |
| Sub-Type | NMDA receptor (NR1/NR2A) |
| Class | Ligand-gated cation channel |
| Therapeutic Area | neurodegeneration & stroke, pain & inflammation, psychiatric disorder, seizure-convulsion |
| Gene Name | GRIN1/GRIN2A |
| Genbank Accession Number | NM_007327.2, NM_000833.2 |
| Validated Assay/Platform | manual patch clamp |
| References | Danysz W and Parsons CG. 1998. Pharmacol Rev. 50:597-664. Glycine and N-methyl-d-aspartate receptors: Physiological significance and possible therapeutic applications. |
| EZCell Info | |
| Host cell | HEK293 |
| Mycoplasma Status | Negative (MycoAlert Kit) |
| Growth media | DMEM/F12/10% FBS |
| Storage and Packaging | |
| Packaging | Cryopreserved cells, 6x106 cells/vial |
| Storage Recommendation | liquid nitrogen |
| Quantity | 6 million cells |
